Cargando…

Epidemiology of Venous Thromboembolism After Second Cancer

BACKGROUND: Venous thromboembolism (VTE) is a serious, yet preventable, complication in cancer. Some patients are diagnosed with a second cancer; however, little is known about the epidemiology of VTE in this population. METHODS: From Danish national healthcare registries, we studied all patients di...

Descripción completa

Detalles Bibliográficos
Autores principales: Gade, Inger Lise, Severinsen, Marianne Tang, Kragholm, Kristian Hay, Kristensen, Søren Risom, Torp-Pedersen, Christian, Riddersholm, Signe Juul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152787/
https://www.ncbi.nlm.nih.gov/pubmed/32308493
http://dx.doi.org/10.2147/CLEP.S247823
_version_ 1783521547612323840
author Gade, Inger Lise
Severinsen, Marianne Tang
Kragholm, Kristian Hay
Kristensen, Søren Risom
Torp-Pedersen, Christian
Riddersholm, Signe Juul
author_facet Gade, Inger Lise
Severinsen, Marianne Tang
Kragholm, Kristian Hay
Kristensen, Søren Risom
Torp-Pedersen, Christian
Riddersholm, Signe Juul
author_sort Gade, Inger Lise
collection PubMed
description BACKGROUND: Venous thromboembolism (VTE) is a serious, yet preventable, complication in cancer. Some patients are diagnosed with a second cancer; however, little is known about the epidemiology of VTE in this population. METHODS: From Danish national healthcare registries, we studied all patients diagnosed with a first breast, prostate, lung, or colorectal cancer from 1995 to 2015. We estimated incidence rates (IRs) of VTE according to the timing of the diagnosis of a second cancer. We controlled for confounder variables in Poisson regression models. RESULTS: In total, 309,077 patients with a first breast, prostate, lung, or colorectal cancer were included in the study. A second cancer was diagnosed in 20,090 (6.5%) of these patients. In total, 11,908 VTEs were observed in the study period, 786 of these occurred after a diagnosis of second cancer. Second cancer types such as pancreas and stomach cancer were associated with fivefold higher IRs of VTE compared with second cancer types such as breast and prostate cancer. The IR of VTE was highest within the first 6 months after the second cancer was diagnosed (IR 40.5 per 1000 person-years, 95% CI 36.3–42.2) with no differences based on how long since the first cancer it was diagnosed. CONCLUSION: The epidemiology of VTE after a second cancer is similar to the epidemiology of VTE after a first cancer with higher rates within the first months after aggressive second cancer types.
format Online
Article
Text
id pubmed-7152787
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-71527872020-04-17 Epidemiology of Venous Thromboembolism After Second Cancer Gade, Inger Lise Severinsen, Marianne Tang Kragholm, Kristian Hay Kristensen, Søren Risom Torp-Pedersen, Christian Riddersholm, Signe Juul Clin Epidemiol Original Research BACKGROUND: Venous thromboembolism (VTE) is a serious, yet preventable, complication in cancer. Some patients are diagnosed with a second cancer; however, little is known about the epidemiology of VTE in this population. METHODS: From Danish national healthcare registries, we studied all patients diagnosed with a first breast, prostate, lung, or colorectal cancer from 1995 to 2015. We estimated incidence rates (IRs) of VTE according to the timing of the diagnosis of a second cancer. We controlled for confounder variables in Poisson regression models. RESULTS: In total, 309,077 patients with a first breast, prostate, lung, or colorectal cancer were included in the study. A second cancer was diagnosed in 20,090 (6.5%) of these patients. In total, 11,908 VTEs were observed in the study period, 786 of these occurred after a diagnosis of second cancer. Second cancer types such as pancreas and stomach cancer were associated with fivefold higher IRs of VTE compared with second cancer types such as breast and prostate cancer. The IR of VTE was highest within the first 6 months after the second cancer was diagnosed (IR 40.5 per 1000 person-years, 95% CI 36.3–42.2) with no differences based on how long since the first cancer it was diagnosed. CONCLUSION: The epidemiology of VTE after a second cancer is similar to the epidemiology of VTE after a first cancer with higher rates within the first months after aggressive second cancer types. Dove 2020-04-08 /pmc/articles/PMC7152787/ /pubmed/32308493 http://dx.doi.org/10.2147/CLEP.S247823 Text en © 2020 Gade et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gade, Inger Lise
Severinsen, Marianne Tang
Kragholm, Kristian Hay
Kristensen, Søren Risom
Torp-Pedersen, Christian
Riddersholm, Signe Juul
Epidemiology of Venous Thromboembolism After Second Cancer
title Epidemiology of Venous Thromboembolism After Second Cancer
title_full Epidemiology of Venous Thromboembolism After Second Cancer
title_fullStr Epidemiology of Venous Thromboembolism After Second Cancer
title_full_unstemmed Epidemiology of Venous Thromboembolism After Second Cancer
title_short Epidemiology of Venous Thromboembolism After Second Cancer
title_sort epidemiology of venous thromboembolism after second cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152787/
https://www.ncbi.nlm.nih.gov/pubmed/32308493
http://dx.doi.org/10.2147/CLEP.S247823
work_keys_str_mv AT gadeingerlise epidemiologyofvenousthromboembolismaftersecondcancer
AT severinsenmariannetang epidemiologyofvenousthromboembolismaftersecondcancer
AT kragholmkristianhay epidemiologyofvenousthromboembolismaftersecondcancer
AT kristensensørenrisom epidemiologyofvenousthromboembolismaftersecondcancer
AT torppedersenchristian epidemiologyofvenousthromboembolismaftersecondcancer
AT riddersholmsignejuul epidemiologyofvenousthromboembolismaftersecondcancer